Epicrispr Biotechnologies raised $90 million in a Series C round to advance its epigenetic therapy EPI-321 for facioscapulohumeral muscular dystrophy, a rare muscle disease with no approved treatments.
The funding, co‑led by Octagon Capital and Janus Henderson Investors, supports pivotal clinical development of EPI-321 and broader investments in Epicrispr’s epigenetic editing platform.
Early clinical data from an ongoing Phase 1/2 trial show that EPI-321 increased lean muscle mass in FSHD patients after a single infusion, with no serious adverse events reported.
Sources:
Epicrispr bags $90M to rewrite treatment of rare muscle disease
Epicrispr lands $90M to advance epigenetic editing drug for rare ...
Epicrispr raises $90m to advance muscular dystrophy therapy
Epicrispr Biotechnologies raises $90 Million Series C round ... - Fundz
Epicrispr Bio CEO Amber Salzman raises $90M to fight FSHD - San ...
Epicrispr Biotechnologies Named to Fast Company's ...
Next-generation CRISPR company raises $68 million, zeroes in on first clinical trial
Epicrispr gene silencer enhances muscle in muscular ...
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle ...
News - Epicrispr Biotechnologies
Epicrispr Gene Silencer Boosts Muscle in Dystrophy
Epicrispr banks $68M to test epigenetic editing on rare muscle disease